White House Reviews Plan on CBD, Marijuana Research

The administration is looking at federal guidance for FDA research on CBD and marijuana. 

June 12, 2020

WASHINGTON—Last week, the U.S. Food and Drug Administration (FDA) submitted a plan for  CBD and marijuana research to the White House Office of Management and Budget, the Boston Globe reports.

The administration released few details about the “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” document. However, an agency spokesperson told the Marijuana Moment group the guidance is related to current work on general CBD rules that might one day let CBD products be marketed as food products or dietary supplements.

“We recognize that there is substantial public interest in marketing and accessing CBD for a variety of products. We are working toward a goal of providing additional guidance, and have made substantial progress,” the agency said in a statement. “There are many questions to explore regarding the science, safety, effectiveness and quality of products containing CBD, and we need to do our due diligence.”

It’s unclear whether the agency will hold off on finalizing specific guidance until the research is finished prior to releasing final regulations for general CBD products. “We will continue to update the public about our path forward as our work progresses and provide information that is based on sound science and data,” FDA said.

Earlier this year, the FDA said it would publish cannabis research guidance in 2020. The agency also seeks public comments about CBD safety and efficacy. As the process continues, the FDA is alerting CBD sellers making especially fanciful or unauthorized claims about CBD therapeutic properties.